Morten Hoyer

Summary

Affiliation: Aarhus University Hospital
Country: Denmark

Publications

  1. ncbi Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma
    Morten Hoyer
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Radiother Oncol 76:48-53. 2005
  2. ncbi Phase II study on stereotactic body radiotherapy of colorectal metastases
    Morten Hoyer
    Department of Oncology, Aarhus University Hospital
    Acta Oncol 45:823-30. 2006
  3. ncbi Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries
    Pia Baumann
    Division of Oncology and Hospital Physics, Radiumhemmet Karolinska University Hospital, Sweden
    Acta Oncol 45:787-95. 2006

Collaborators

  • Cai Grau
  • Anders Traberg Hansen
  • J Nyman
  • Pia Baumann
  • Elisabeth Morhed
  • Suzanne Rehn Ericsson
  • Rolf Lewensohn
  • Lena Wittgren
  • Karl-Axel Johansson
  • Signe Friesland
  • Ingmar Lax
  • Lars Ekberg
  • Merete Paludan
  • Henrik Blomgren

Detail Information

Publications3

  1. ncbi Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma
    Morten Hoyer
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Radiother Oncol 76:48-53. 2005
    ..Stereotactic radiotherapy (SRT) may be an alternative treatment for patients with locally advanced disease. The effect of SRT was investigated in the present phase-II trial...
  2. ncbi Phase II study on stereotactic body radiotherapy of colorectal metastases
    Morten Hoyer
    Department of Oncology, Aarhus University Hospital
    Acta Oncol 45:823-30. 2006
    ..One toxic death and few severe reactions were observed. For the majority of patients, the treatment related toxicity was moderate...
  3. ncbi Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries
    Pia Baumann
    Division of Oncology and Hospital Physics, Radiumhemmet Karolinska University Hospital, Sweden
    Acta Oncol 45:787-95. 2006
    ..EQD2 (> v.s.<55.6 Gy) showed a statistically significant benefit survival for the higher doses. SBRT for stage I NSCLC results in favourable local control not inferior to fractionated RT and with acceptable toxicity...